Subacute Cutaneous Lupus Erythematosus Associated with Ramucirumab Therapy

Main Article Content

Elise Hogan
Kelsey Nusbaum
Anne Householder


subacute cutaneous lupus erythematosus, lupus, rash, monoclonal antibodies, ramucirumab, cytotoxic dermatitis, drug-induced, drug-induced SCLE


Abstract not available. 


1. Cojocaru, M., Cojocaru, I. M., Silosi, I., & Vrabie, C. D. Manifestations of systemic lupus erythematosus. Maedica, (2011), 6(4), 330–336. [PMID: 22879850]

2. Reed BR, Huff JC, Jones SK, et al. Subacute cutaneous lupus erythematosus associated with hydrochlorothiazide therapy. Ann Intern Med. 1985 Jul;103(1):49-51. [PMID: 3873891].

3. Bolton C, Chen Y, Hawthorne R, et al. Systematic Review: Monoclonal Antibody-Induced Subacute Cutaneous Lupus Erythematosus. Drugs R D. 2020 Dec;20(4):319-330. [PMID: 32960413].

4. Zhu AX, Kang YK, Yen CJ, et al. REACH-2 study investigators. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019 Feb;20(2):282-296. [PMID: 30665869].

5. Cleaver N, Ramirez J, Gildenberg S. Cutaneous lupus erythematosus in a patient undergoing intravitreal bevacizumab injections: case report and review of the literature. J Drugs Dermatol. 2013 Sep;12(9):1052-5. [PMID: 24002156].

6. Andric M, Dixit S, Robaei D, Watchorn R, Verma N. A case of subacute cutaneous lupus erythematosus as a result of ranibizumab (Lucentis) treatment. Indian J Ophthalmol. 2013 Dec;61(12):752-4. [PMID: 24212210].